Waldenstrom macroglobulinemia is a rare indolent B-cell lymphoplasmacytic lymphoma characterized by bone marrow infiltration and monoclonal IgM overproduction. Clinical complications include hyperviscosity, neuropathy, anemia, and constitutional symptoms.
Cellectar reported 12-month follow-up from the Phase 2b CLOVER WaM trial of iopofosine I 131 in relapsed or refractory Waldenström macroglobulinemia. In 55 patients, ORR was 83.6%, MRR was 61.8% and median duration of response was 17.8 months.
Cellectar Biosciences expanded its global IP estate and announced oversubscribed financing of up to $140 million. The funding supports iopofosine I 131 regulatory filings and a confirmatory study in Waldenström macroglobulinemia.
Recent studies demonstrate zanubrutinib delivers higher response rates, longer treatment persistence, and lower healthcare costs compared to acalabrutinib and ibrutinib across multiple B-cell malignancies, with particularly strong benefits in high-risk populations.
AbbVie is testing venetoclax in a Phase 2 study for adults with relapsed or refractory Waldenström macroglobulinemia or lymphoplasmacytic lymphoma in Japan, aiming to expand the drug into rare blood cancers.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06986174 |
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia |
RECRUITING | PHASE2 |
| NCT06224309 |
Preliminary Assessment of [18F]BL40 in PET/CT Scans |
NOT_YET_RECRUITING | |
| NCT05294731 |
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader |
RECRUITING | PHASE1/PHASE2 |
| NCT05006716 |
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies |
RECRUITING | PHASE1/PHASE2 |
| NCT04463953 |
Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia |
COMPLETED | PHASE2 |
| NCT04052854 |
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies |
NO_LONGER_AVAILABLE | |
| NCT03187262 |
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia |
COMPLETED | PHASE2 |
| NCT02933320 |
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia |
COMPLETED | PHASE1/PHASE2 |
| NCT02844361 |
Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia |
COMPLETED | PHASE4 |
| NCT02844322 |
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia |
COMPLETED | PHASE4 |
